Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Level BiotechnologyROCO:3118 77 OCF Margin % is 17.78% as of Dec. 2025, which is 52% above its 10-year median of 11.66. GuruFocus rates ROCO:3118 with a GF Score™ of 77/100 and a GF Value™ of NT$35.57 (Modestly Undervalued). The stock has 2 warning signs investors should review. Among 950 Biotechnology companies, Level Biotechnology ranks better than 74.32% on this metric.
The historical rank and industry rank for Level Biotechnology's OCF Margin % or its related term are showing as below:
ROCO:3118'
s OCF Margin % Range Over the Past 10 Years
Min: 4.26 Med: 11.66 Max: 23.03
Current: 8.09
During the past 13 years, the highest OCF Margin % of Level Biotechnology was 23.03%. The lowest was 4.26%. And the median was 11.66%.
ROCO:3118's OCF Margin % is ranked better than 74.32% of 950
companies
in the Biotechnology industry
Industry Median: -64.565
vs ROCO:3118: 8.09
Level Biotechnology OCF Margin % Related Terms
Level Biotechnology OCF Margin % Historical Data
* Premium members only.
The historical data trend for Level Biotechnology's OCF Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ROCO:3118 vs VRTX, REGN, ALNY: OCF Margin % Comparison
For the Biotechnology subindustry, Level Biotechnology's OCF Margin %, along with its competitors' market caps and OCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Level Biotechnology OCF Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Level Biotechnology's OCF Margin % distribution charts can be found below:
* The bar in red indicates where Level Biotechnology's OCF Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Level Biotechnology (ROCO:3118) has a OCF Margin % of 17.78% as of Dec. 2025. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on Level Biotechnology and its competitors. This is 52% above median its historical median of 11.66. Over the past decade, Level Biotechnology's OCF Margin % has ranged from 4.26 to 23.03. According to the industry distribution chart, Level Biotechnology ranks #244 out of 950 companies in the Biotechnology industry, placing it in the top 25.7%.
Is Level Biotechnology's OCF Margin % too high?
Level Biotechnology's current OCF Margin % of 17.78% is 52% above median its 10-year median of 11.66. Over the past 10 years, this metric has ranged from a low of 4.26 to a high of 23.03. Based on the distribution chart, Level Biotechnology ranks #244 out of 950 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Level Biotechnology has a GF Score™ of 77/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Level Biotechnology's OCF Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Level Biotechnology ranks #244 out of 950 companies for OCF Margin %. This puts Level Biotechnology in the upper half of its industry. Historically, Level Biotechnology's own OCF Margin % has ranged from 4.26 to 23.03 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good OCF Margin % for a Biotechnology company?
A good OCF Margin % depends on the Biotechnology industry context. However, OCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high OCF Margin % mean?
A high OCF Margin % can signal that a stock is expensive relative to its fundamentals. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on Level Biotechnology and its competitors. Level Biotechnology's current OCF Margin % is 17.78%, which is 52% above median its own 10-year median of 11.66. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Level Biotechnology stock overvalued right now?
Based on GuruFocus' analysis, Level Biotechnology (ROCO:3118) is currently considered Modestly Undervalued. The stock's GF Value™ is NT$35.57, compared to a current price of NT$31.75 — trading 10.7% below its estimated fair value. The current OCF Margin % is 17.78%, which is 52% above median its 10-year median of 11.66. Level Biotechnology's overall GF Score™ is 77/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is OCF Margin % calculated?
OCF Margin % is calculated from a company's financial statements. For Level Biotechnology (ROCO:3118), the current OCF Margin % is 17.78% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Level Biotechnology (ROCO:3118) Overvalued in 2026?
Based on GuruFocus' analysis, Level Biotechnology stock appears to be undervalued.
The current stock price of NT$31.75 is trading 10.7% below its estimated GF Value™ of NT$35.57.
GuruFocus considers Level Biotechnology to be Modestly Undervalued.
Key valuation signals for ROCO:3118:
OCF Margin %: 17.78% (52% above median its 10-year median of 11.66)
GF Value™: NT$35.57 vs. price of NT$31.75 (10.7% below fair value)
No single metric tells the full story. See the ROCO:3118 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Level Biotechnology Inc is a Taiwan-based company engaged in the sales of biomedical products and providing preclinical testing services. The company has three reportable segments: Department A and B, Department C, and Department D. Department A and Department B sell the cell culture consumables and the antibody reagents, Department C sells the instruments and equipment, and Department D provides CRO services. The majority of revenue is derived from the Department A and B.
77GF Score
Get the complete analysis for ROCO:3118
OCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:3118 has been successfully added to your 
